Calithera Biosciences is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The Company's lead product candidate in tumor metabolism, CB-839, is an internally discovered, first-in-class inhibitor of glutaminase, a critical enzyme in tumor metabolism. Calithera is currently evaluating CB-839 in three Phase 1 clinical trials in solid and hematological tumors.
In tumor immunology, the Company's lead preclinical program is directed at developing inhibitors of the enzyme arginase and may provide a first-in-class therapeutic agent for this novel target. Calithera Biosciences's ongoing research efforts are focused on discovering additional product candidates against novel tumor metabolism and immunology targets.
Revenue (Q1, 2018)
Net income (Q1, 2018)
EBIT (Q1, 2018)
Market capitalization (21-May-2018)
Closing share price (21-May-2018)
Phase 1/2 Trials Products
Phase I Trials Products